Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARVN Stock Forecast 2025-2026
$6.61
Current Price
$482.47M
Market Cap
Buy 13
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to ARVN Price Targets
+1,564.1%
To High Target of $110.00
+126.9%
To Median Target of $15.00
+21.0%
To Low Target of $8.00
ARVN Price Momentum
-13.4%
1 Week Change
-4.9%
1 Month Change
-79.0%
1 Year Change
-65.5%
Year-to-Date Change
-82.3%
From 52W High of $37.38
+11.3%
From 52W Low of $5.94
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Arvinas (ARVN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ARVN and similar high-potential opportunities.
Latest ARVN Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, ARVN has a bullish consensus with a median price target of $15.00 (ranging from $8.00 to $110.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $6.61, the median forecast implies a 126.9% upside. This outlook is supported by 13 Buy, 8 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Paul Choi at Goldman Sachs, suggesting a 21.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARVN Analyst Ratings
13
Buy
8
Hold
0
Sell
ARVN Price Target Range
Low
$8.00
Average
$15.00
High
$110.00
Current: $6.61
Latest ARVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $11.00 |
| May 5, 2025 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $10.00 |
| May 5, 2025 | Truist Securities | Srikripa Devarakonda | Hold | Downgrade | $11.00 |
| May 5, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $9.50 |
| May 2, 2025 | Jefferies | Akash Tewari | Hold | Downgrade | $10.00 |
| May 2, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $8.00 |
| May 2, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $16.00 |
| May 2, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $16.00 |
| May 2, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $19.00 |
| May 2, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $14.00 |
| May 2, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $24.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $12.00 |
| Apr 9, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $21.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $81.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $81.00 |
| Mar 13, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $32.00 |
| Mar 13, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $12.00 |
| Mar 12, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $26.00 |
| Mar 12, 2025 | BMO Capital | Etzer Darout | Outperform | Maintains | $20.00 |
| Mar 12, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $28.00 |
Arvinas Inc. (ARVN) Competitors
The following stocks are similar to Arvinas based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arvinas Inc. (ARVN) Financial Data
Arvinas Inc. has a market capitalization of $482.47M with a P/E ratio of -2.4x. The company generates $426.90M in trailing twelve-month revenue with a -10.9% profit margin.
Revenue growth is +646.2% quarter-over-quarter, while maintaining an operating margin of +37.8% and return on equity of -7.3%.
Valuation Metrics
Market Cap
$482.47M
Enterprise Value
$-461,326,912
P/E Ratio
-2.4x
PEG Ratio
-1.4x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
+646.2%
Gross Margin
N/A
Operating Margin
+37.8%
Net Margin
-10.9%
EPS Growth
+646.2%
Financial Health
Cash/Price Ratio
+197.8%
Current Ratio
4.6x
Debt/Equity
1.6x
ROE
-7.3%
ROA
-5.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Arvinas Inc. (ARVN) Business Model
About Arvinas Inc.
What They Do
Develops innovative protein degradation therapies.
Business Model
The company focuses on creating novel treatments for difficult diseases by utilizing its proprietary PROTAC technology. This platform allows Arvinas to target and degrade disease-causing proteins, thereby generating revenue through partnerships, licensing agreements, and potential market sales of successful therapies.
Additional Information
Founded in 2013 and based in New Haven, Connecticut, Arvinas is at the forefront of biotechnology, conducting clinical trials to validate its approaches. Its unique technology positions it as a leader in addressing previously undruggable targets, particularly in cancer and neurodegenerative diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
430
CEO
Dr. John G. Houston Ph.D.
Country
United States
IPO Year
2018
Website
www.arvinas.comArvinas Inc. (ARVN) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for investors of Arvinas, Inc. (NASDAQ:ARVN). Interested parties can contact Danielle Peyton for more information.
Why It Matters
The investigation into Arvinas may indicate potential legal issues or financial discrepancies, which could impact stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Arvinas, Inc. (NASDAQ:ARVN) investors. Affected investors can find more information at bgandg.com/ARVN.
Why It Matters
The investigation into Arvinas could indicate potential legal issues or financial irregularities, impacting the company's stock value and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Arvinas, Inc. (NASDAQ:ARVN) for potential federal securities law violations following a May 1 announcement about changes to its vepdegestrant development plan.
Why It Matters
The investigation into Arvinas for potential securities law violations raises concerns over compliance and governance, which could impact stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Arvinas, Inc. (NASDAQ:ARVN) investors. Interested parties can find more information at bgandg.com/ARVN.
Why It Matters
The investigation into Arvinas may signal potential legal issues or financial instability, affecting investor confidence and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Arvinas, Inc. (NASDAQ:ARVN) for potential federal securities law violations following a May 1 press release on its vepdegestrant development plan changes.
Why It Matters
The investigation into Arvinas for potential securities law violations raises concerns about its credibility and future prospects, impacting investor confidence and stock valuation.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors in Arvinas, Inc. (NASDAQ: ARVN). Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation into Arvinas could signal potential legal issues or financial instability, prompting investors to reassess their positions and exposure to the company.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About ARVN Stock
What is Arvinas Inc.'s (ARVN) stock forecast for 2025?
Based on our analysis of 26 Wall Street analysts, Arvinas Inc. (ARVN) has a median price target of $15.00. The highest price target is $110.00 and the lowest is $8.00.
Is ARVN stock a good investment in 2025?
According to current analyst ratings, ARVN has 13 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARVN stock?
Wall Street analysts predict ARVN stock could reach $15.00 in the next 12 months. This represents a 126.9% increase from the current price of $6.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arvinas Inc.'s business model?
The company focuses on creating novel treatments for difficult diseases by utilizing its proprietary PROTAC technology. This platform allows Arvinas to target and degrade disease-causing proteins, thereby generating revenue through partnerships, licensing agreements, and potential market sales of successful therapies.
What is the highest forecasted price for ARVN Arvinas Inc.?
Price targets from Wall Street analysts for ARVN are not currently available. The stock is trading at $6.61.
What is the lowest forecasted price for ARVN Arvinas Inc.?
The lowest price target for ARVN is $8.00 from Paul Choi at Goldman Sachs, which represents a 21.0% increase from the current price of $6.61.
What is the overall ARVN consensus from analysts for Arvinas Inc.?
The overall analyst consensus for ARVN is bullish. Out of 26 Wall Street analysts, 13 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are ARVN stock price projections?
Stock price projections, including those for Arvinas Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 4:49 PM UTC